▶ Presentation of Plasmapp’s implant surface treatment technology at the best dental education conference in the United States.

▶ Entering the U.S. dental market in earnest, receiving great attention from implant clinicians, researchers, and auxiliary experts

Plasmapp (405000), a bio-plasma deep tech company, participated in America's best dental education conference (Academy of Osseointegration) held in Charlotte, USA from March 7th to 9th.

At a conference presentation by a faculty member at Harvard University (Harvard School of Dental Medicine), Plasmapp's surface treatment technology was presented, receiving great attention from implant clinicians, researchers, and assistant experts, and the company is beginning to enter the U.S. dental market in earnest.

In a preclinical study using large animals in October last year, Harvard faculty found that plasma surface treatment increased bone-to-implant contact and reduced marginal bone loss, enabling faster healing and implant surgery for patients. Research results that could increase the success rate were published in an SCI-level paper in October last year.

At this conference, professors at Harvard University in the U.S. conducted cell experiment research using Plasmapp's surface treatment device and experimentally verified that plasma surface treatment on the titanium surface significantly increases hydrophilicity and significantly increases the response of osteoblasts and fibroblasts. It is evaluated that it has revealed the mechanism of Plasmapp's surface treatment technology and added to the reliability of the technology.

Youbong Lim, CEO of Plasmapp, said, “In the process of developing and commercializing the world's first implant surface treatment technology, we are collaborating with the world's best research institutions and are in the process of obtaining approval for new medical devices in the United States.” He added, “Plasmapp is a global company. “We are creating a new implant standard in the dental market, and we will contribute to increasing the surgical success rate of medical implants by expanding our application to various implants used in plastic surgery and orthopedics,” he said.

▲ Hydrophilicity change and osteoblast response performance results according to plasma surface treatment announced by Harvard University

<Photo provided by Plasmapp>